132 related articles for article (PubMed ID: 9893669)
1. Expression of genes involved in nucleotide excision repair and sensitivity to cisplatin and melphalan in human cancer cell lines.
Damia G; Guidi G; D'Incalci M
Eur J Cancer; 1998 Oct; 34(11):1783-8. PubMed ID: 9893669
[TBL] [Abstract][Full Text] [Related]
2. Sensitivity of CHO mutant cell lines with specific defects in nucleotide excision repair to different anti-cancer agents.
Damia G; Imperatori L; Stefanini M; D'Incalci M
Int J Cancer; 1996 Jun; 66(6):779-83. PubMed ID: 8647649
[TBL] [Abstract][Full Text] [Related]
3. Enhanced host cell reactivation capacity and expression of DNA repair genes in human breast cancer cells resistant to bi-functional alkylating agents.
Yen L; Woo A; Christopoulopoulos G; Batist G; Panasci L; Roy R; Mitra S; Alaoui-Jamali MA
Mutat Res; 1995 Nov; 337(3):179-89. PubMed ID: 7491121
[TBL] [Abstract][Full Text] [Related]
4. DNA repair capacity: inconsistency between effect of over-expression of five NER genes and the correlation to mRNA levels in primary lymphocytes.
Vogel U; Dybdahl M; Frentz G; Nexo BA
Mutat Res; 2000 Nov; 461(3):197-210. PubMed ID: 11056291
[TBL] [Abstract][Full Text] [Related]
5. Sensitization to the cytotoxicity of cisplatin by transfection with nucleotide excision repair gene xeroderma pigmentosun group A antisense RNA in human lung adenocarcinoma cells.
Wu X; Fan W; Xu S; Zhou Y
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5874-9. PubMed ID: 14676109
[TBL] [Abstract][Full Text] [Related]
6. Downregulation of RIF1 Enhances Sensitivity to Platinum-Based Chemotherapy in Epithelial Ovarian Cancer (EOC) by Regulating Nucleotide Excision Repair (NER) Pathway.
Liu YB; Mei Y; Tian ZW; Long J; Luo CH; Zhou HH
Cell Physiol Biochem; 2018; 46(5):1971-1984. PubMed ID: 29719287
[TBL] [Abstract][Full Text] [Related]
7. DNA repair protein levels vis-à-vis anticancer drug resistance in the human tumor cell lines of the National Cancer Institute drug screening program.
Xu Z; Chen ZP; Malapetsa A; Alaoui-Jamali M; Bergeron J; Monks A; Myers TG; Mohr G; Sausville EA; Scudiero DA; Aloyz R; Panasci LC
Anticancer Drugs; 2002 Jun; 13(5):511-9. PubMed ID: 12045463
[TBL] [Abstract][Full Text] [Related]
8. Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines.
Selvakumaran M; Pisarcik DA; Bao R; Yeung AT; Hamilton TC
Cancer Res; 2003 Mar; 63(6):1311-6. PubMed ID: 12649192
[TBL] [Abstract][Full Text] [Related]
9. Nucleotide excision repair protein levels vis-à-vis anticancer drug resistance in 60 human tumor cell lines.
Chen ZP; Malapetsa A; Monks A; Myers TG; Mohr G; Sausville EA; Scudiero DA; Panasci LC
Ai Zheng; 2002 Mar; 21(3):233-9. PubMed ID: 12451985
[TBL] [Abstract][Full Text] [Related]
10. A truncated human xeroderma pigmentosum complementation group A protein expressed from an adenovirus sensitizes human tumor cells to ultraviolet light and cisplatin.
Rosenberg E; Taher MM; Kuemmerle NB; Farnsworth J; Valerie K
Cancer Res; 2001 Jan; 61(2):764-70. PubMed ID: 11212280
[TBL] [Abstract][Full Text] [Related]
11. Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells: role of ERCC1-XPF.
Ferry KV; Hamilton TC; Johnson SW
Biochem Pharmacol; 2000 Nov; 60(9):1305-13. PubMed ID: 11008124
[TBL] [Abstract][Full Text] [Related]
12. Modulation of melphalan and cisplatin cytotoxicity in human ovarian cancer cells resistant to alkylating drugs.
Gornati D; Zaffaroni N; Villa R; De Marco C; Silvestrini R
Anticancer Drugs; 1997 Jun; 8(5):509-16. PubMed ID: 9215615
[TBL] [Abstract][Full Text] [Related]
13. [Enhancement effect of nucleotide excision repair gene xeroderma pigmentosun group a antisense RNA on sensitivity of human lung adenocarcinoma cell line A549 to cisplatin].
Fan W; Zhang HL; Wu XM
Ai Zheng; 2005 Apr; 24(4):403-7. PubMed ID: 15820060
[TBL] [Abstract][Full Text] [Related]
14. Xeroderma pigmentosum complementation group C single-nucleotide polymorphisms in the nucleotide excision repair pathway correlate with prolonged progression-free survival in advanced ovarian cancer.
Fleming ND; Agadjanian H; Nassanian H; Miller CW; Orsulic S; Karlan BY; Walsh CS
Cancer; 2012 Feb; 118(3):689-97. PubMed ID: 21751198
[TBL] [Abstract][Full Text] [Related]
15. The NER proteins XPC and CSB, but not ERCC1, regulate the sensitivity to the novel DNA binder S23906: implications for recognition and repair of antitumor alkylators.
Rocca CJ; Poindessous V; Soares DG; Ouadrani KE; Sarasin A; Guérin E; de Gramont A; Henriques JA; Escargueil AE; Larsen AK
Biochem Pharmacol; 2010 Aug; 80(3):335-43. PubMed ID: 20399198
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of Gli1 results in altered c-Jun activation, inhibition of cisplatin-induced upregulation of ERCC1, XPD and XRCC1, and inhibition of platinum-DNA adduct repair.
Kudo K; Gavin E; Das S; Amable L; Shevde LA; Reed E
Oncogene; 2012 Nov; 31(44):4718-24. PubMed ID: 22266871
[TBL] [Abstract][Full Text] [Related]
17. Regulation of DNA repair gene expression in human cancer cell lines.
McGurk CJ; Cummings M; Köberle B; Hartley JA; Oliver RT; Masters JR
J Cell Biochem; 2006 Apr; 97(5):1121-36. PubMed ID: 16315315
[TBL] [Abstract][Full Text] [Related]
18. Absence of evidence for allelic loss or allelic gain for ERCC1 or for XPD in human ovarian cancer cells and tissues.
Yu JJ; Bicher A; Ma YK; Bostick-Bruton F; Reed E
Cancer Lett; 2000 Apr; 151(2):127-32. PubMed ID: 10738106
[TBL] [Abstract][Full Text] [Related]
19. Differential contributory roles of nucleotide excision and homologous recombination repair for enhancing cisplatin sensitivity in human ovarian cancer cells.
Wang QE; Milum K; Han C; Huang YW; Wani G; Thomale J; Wani AA
Mol Cancer; 2011 Mar; 10():24. PubMed ID: 21385444
[TBL] [Abstract][Full Text] [Related]
20. The functional status of DNA repair pathways determines the sensitization effect to cisplatin in non-small cell lung cancer cells.
Chen P; Li J; Chen YC; Qian H; Chen YJ; Su JY; Wu M; Lan T
Cell Oncol (Dordr); 2016 Dec; 39(6):511-522. PubMed ID: 27473273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
